World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 9 November 2020
Main ID:  EUCTR2014-005112-42-FR
Date of registration: 22/06/2015
Prospective Registration: Yes
Primary sponsor: INSERM
Public title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)
Scientific title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)
Date of first enrolment: 22/06/2015
Target sample size: 50
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005112-42
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
France Netherlands
Contacts
Name: Sonia GUEGUEN   
Address:  8 rue de la Croix Jarry 75013 Paris France
Telephone: 33144236041
Email: rqrc.siege@inserm.fr
Affiliation:  INSERM
Name: Sonia GUEGUEN   
Address:  8 rue de la Croix Jarry 75013 Paris France
Telephone: 33144236041
Email: rqrc.siege@inserm.fr
Affiliation:  INSERM
Key inclusion & exclusion criteria
Inclusion criteria:
- positive genetic test with CAG repeat lenght = 39 in HTT gene
- at lmeast 18 years of age
- signature of informed consent
- covered by social security
- UHDRS score between 5 and 40
- Ability to undergo MRI scanning
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 100
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
- Hypersensitivity to triheptanoin or to one of its excipients
- additional psychiatric or neurological conditions
- severe head injury
- Participation in another therapeutical trial ( 3 months exclusion period)
- Pregnancy or breastfeeding
- Inability to understand information about the protocol
- persons deprived of their liberty by judicial or unable to consent
- adult subject under legal protection or unable to consent
- Patients under tetrabenazine and neuroleptics other than atypical neuroleptics at a small dose


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Huntington's disease
MedDRA version: 18.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders
Intervention(s)

Product Name: Triheptanoin
Product Code: UX007
Pharmaceutical Form: Oral solution
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use

Primary Outcome(s)
Main Objective: the primary objectice is to evaluate the efficacy of triheptanoin in
- increasing the energy response in the metabolic profile of the brain of early affected HD patients , as captured by 31-Phosphorus Magnetic Resonance Spectroscopy
- slowing atrophy in the caudate of early affected HD patients as measured with volumetric resonance imaging
Primary end point(s): - an increase in the index of brain energy restoration as defined by the difference between Pi/PCr ration during visual stimulation and the mean of Pi/PCr ratio during rest and recovery using 31P-MRS after 3 months
- a decrease in the rate of caudate atrophy, using volumetric MRI, after six months of treatment with triheptanoin in early HD patients
Secondary Objective: - to assess the clinical benefit of triheptanoin on motor function in HD patients using scores on the United Huntington's Disease Rating Scale
- to assess the clinical benefit of triheptanoin on cognitive function ansd psychiatric symptoms in HD patients using scores on the symbol digit test, PBA-S and the HVLT-R
- to assess the effect on quality of life (SF-36) of HD patients of therapeutic use of triheptanoin
-to confirm long term clinical and biological tolerance of triheptanoin in HD patients
- to evaluate long-term compliance with dietary modifications in HD patients
- o look for correlations between neuroimaging volumetric parameters; brain energy profiles and clinical scores, beofre avec after treatment.
Secondary Outcome(s)
Timepoint(s) of evaluation of this end point: a) 6 months and 1 year of treatment
b) 1 year
c) 6 months and 1 year
d) 1 year
Secondary end point(s): a) increase in the index of brain energy restoration using 31P-MRS
b) decrease in the rate of caudate atrophy after 1 year of treatment with triheptanoin in early affected HD patient.
c) the clinical benefit of triheptanoin will be evaluated by a decrease in the progression of the UHDRS over 6 months ans 1 year of treatment.
d) it will be also evaluated using SMDT
e) The benefit of triheptnaoin use on patient quality of life will be evaluated by using the SFR-36
f) long term compliance will be performed by regular bioclinical testing from blood abd urine samples
g) Long term tolerance will be confirmed by clinical exam and by patient phone call
h) changes in brain energy will be correlated with volumetric measures ans clinical rating scale scores.
Secondary ID(s)
C14-62
Source(s) of Monetary Support
Ultragenyx Pharmaceutical
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 12/06/2015
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey